Medicinal composition and application of bendamustine

A technology of bendamustine and bendamustine hydrochloride, which is applied in the field of pharmaceutical compositions for tumor diseases and autoimmune diseases, can solve the problems of physical damage to patients, time-consuming, increased failure and impurities, etc., and achieve reduction Injection volume, shortening infusion time, and avoiding the effect of curative effect reduction

Active Publication Date: 2019-12-13
NANJING BAIXINYU PHARM CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The problem in clinical use is that it is difficult to reconstitute the existing freeze-dried powder of bendamustine. According to clinical reports, reconstitution takes at least 15 minutes and may take up to 30 minutes
In addition to being cumbersome and time consuming for the health care professional reconstituting the product, prolonged exposure of bendamustine to water during reconstitution increases failure and impurity formation due to the hydrolysis of the product by water possibility of
Secondly, in order to avoid hydrolysis, once the preparation of this product is completed, it needs to be injected intravenously within 30-60 minutes, resulting in poor adaptability of patients
Furthermore, high infusion volume and longer infusion time are associated with many side effects, for example: when currently using bendamustine therapy, large doses of sodium-containing injections need to be infused, for heart diseases (congestive heart failure and / or or renal failure) is contraindicated in patients who would have benefited from treatment with bendamustine, or in the absence of alternative therapy, where patients are forced to accept significant sodium-containing injections physical damage
Also, high infusion volumes place unhealthy stress on the patient's diseased organs, including the heart and kidneys

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition and application of bendamustine
  • Medicinal composition and application of bendamustine
  • Medicinal composition and application of bendamustine

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023]

[0024]

[0025] Take 6%-9% lecithin and 4%-6% cholesterol in a round bottom flask, reverse evaporation, add 2%-3% bendamustine hydrochloride in 10%-20% propylene glycol solution, mix well, add 0.5% sodium metabisulfite, add water for injection to a sufficient amount, adjust the pH to 2-3, the concentration of bendamustine hydrochloride is 25mg / mL, add activated carbon, stir, filter through a 0.45μm membrane to remove carbon, and filter through a 0.22μm membrane Sterilize, pack and serve.

Embodiment 2

[0027]

[0028] Take 6%-9% lecithin and 4%-6% cholesterol in a round bottom flask, reverse evaporation, add 2%-3% bendamustine hydrochloride in 5%-10% glycerol solution, mix well, add 0.5% sodium metabisulfite, add water for injection to a sufficient amount, adjust the pH to 2-3, the concentration of bendamustine hydrochloride is 25mg / mL, add activated carbon, stir, filter through a 0.45μm membrane to remove carbon, and filter through a 0.22μm membrane Sterilize, pack and serve.

Embodiment 3

[0030]

[0031]

[0032] Take 6%-9% lecithin, 4%-6% cholesterol in a round bottom flask, reverse evaporation, add 2%-3% bendamustine hydrochloride in 10%-20% propylene glycol solution, 0.1%-0.5 % Thioglycerol, mix well, add different antioxidants in the table, add water for injection to a sufficient amount, adjust pH to 2-3, bendamustine hydrochloride concentration is 25mg / mL, add activated carbon, stir, 0.45 Filter through a μm membrane to remove carbon, filter through a 0.22 μm membrane to sterilize, and pack in aliquots.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a bendamustine pharmaceutical composition comprising: 1.5%-5% bendamustine or a pharmaceutically acceptable salt or ester or solvate thereof, 0%-20% stabilizer, 0.05%-2 % antioxidant, 0%‑0.008% pH regulator, and the rest exclusive solvent. In clinical use, according to the dosage of the patient, 10-100mL injection can be used to dilute the bendamustine hydrochloride with a final concentration of 0.1mg / mL-10mg / mL for use, and the preliminary stability test shows that the present invention can be used after dilution At 25°C or 5°C, it is stable for 48 hours. Compared with commercially available lyophilized preparations, the volume of diluent used is reduced (the existing lyophilized preparations require 500mL injection to be reconstituted), and the stability of the diluted drug solution Improvement, patient compliance is good, and existing clinical problems are solved.

Description

technical field [0001] The present invention relates to the field of pharmaceutical compositions for neoplastic diseases and autoimmune diseases, especially nitrogen mustard bendamustine, such as bendamustine hydrochloride or a pharmaceutically acceptable ester, salt or solvate thereof combination. Background technique [0002] Bendamustine, chemical name: 4-{5-[di(2-chloroethyl)amino]-1-methyl-2-benzimidazolyl}butanoic acid, structural formula: [0003] [0004] Bendamustine was originally synthesized in the German Democratic Republic (GDR) in 1963, and was developed between 1971 and 1992. The trade name is produced by the Jena pharmaceutical company, and since 1993, it has been used by ribosepharm GmbH as marketed under the trade name. In 2008, the injection bendamustine hydrochloride (Bendamustine Hydrochloride) produced by U.S. Cephalon Company was listed in the U.S. under the trade name For the treatment of relapsed and refractory B-cell non-Hodgkin's lymphoma...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K9/08A61K31/4184A61K47/24A61K47/28A61K47/10A61K47/34A61P35/00A61P35/02
CPCA61K47/28A61K47/34A61K9/0019A61K9/08A61K31/4184A61K47/20A61P35/00A61P37/02
Inventor 靳翔
Owner NANJING BAIXINYU PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap